StreetInsider.com News Articles

Telomir Pharmaceuticals publishes diabetes study results in medical journal

Mon, 15 Jun 2026 08:01:25 -0400

Telomir Pharmaceuticals Inc. (NASDAQ: TELO) announced the publication of preclinical study results showing its compound Telomir-Zn restored insulin sensitivity in a zebrafish model of Type 2 diabetes, according to a company statement.

The study, published in Biomedicine & Pharmacotherapy, examined zebrafish fed a high-calorie diet that developed metabolic dysfunction including hyperglycemia, hyperinsulinemia and insulin resistance with HOMA-IR values of approximately 10-12.

Treatment with Telomir-Zn for 14 days produced dose-dependent improvements in metabolic measures. Fasting blood glucose levels decreased to near control levels, glucose clearance improved during oral glucose tolerance testing, and fasting insulin concentrations were reduced. HOMA-IR values, which measure insulin resistance,

Form 8-K Telomir Pharmaceuticals, For: Jun 15

Mon, 15 Jun 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260615/26644469.html

Form 8-K Telomir Pharmaceuticals, For: Jun 15

Mon, 15 Jun 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260615/26644469.html

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model

Mon, 15 Jun 2026 08:00:00 -0400

Insulin Resistance Was Normalized Following 14 Days of Treatment, Supporting Restoration of Glucose Metabolism and Insulin Sensitivity and Further Validating Telomir-Zn's Metal-Homeostasis Mechanism Across Multiple Disease Models.

MIAMI, FL / ACCESS Newswire / June 15, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced the peer-reviewed publication of preclinical data demonstrating restoration of insulin sensitivity and significant improvement in glucose homeostasis with Telomir-Zn in a diet-induced zebrafish model of Type 2 diabetes

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model

Mon, 15 Jun 2026 08:00:00 -0400

Form 3 Telomir Pharmaceuticals, For: Jun 03 Filed by: Mushak Andriy

Tue, 09 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260609/26624582.html

Form 3 Telomir Pharmaceuticals, For: Jun 03 Filed by: Mushak Andriy

Tue, 09 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260609/26624582.html

Form 8-K Telomir Pharmaceuticals, For: Jun 03

Mon, 08 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260608/26618238.html

Form 8-K Telomir Pharmaceuticals, For: Jun 03

Mon, 08 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260608/26618238.html

Form 4 Telomir Pharmaceuticals, For: May 21 Filed by: Del Giudice Matthew Paul